Improvements in SBM and complete SBM were also significantly greater in the active treatment arms than placebo (Morishita 2021)
This absence of IGF-1 stimulation is critical for appetite neutrality because IGF-1 has known effects on hypothalamic neuropeptide expression, including alterations to neuropeptide Y (NPY) and agouti-related peptide (AgRP), both potent appetite stimulators
However, given the prolonged half-life of phenobarbital, using massive doses is inadvisable
GLP-1s improve systemic insulin sensitivity, reduce vascular inflammation, enhance endothelial function, and modestly lower blood pressure collectively improving blood flow and nutrient delivery to the brain [12]
This article explores the current status of oral GLP-1 drugs, what they mean for diabetes care, and how they may change the treatment landscape